Equities

Can-Fite Biopharma Ltd

Can-Fite Biopharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (ILa)3.80
  • Today's Change0.80 / 26.67%
  • Shares traded49.32m
  • 1 Year change+8.57%
  • Beta0.6453
Data delayed at least 20 minutes, as of Jun 13 2024 15:24 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

  • Revenue in ILS (TTM)2.76m
  • Net income in ILS-28.36m
  • Incorporated1994
  • Employees5.00
  • Location
    Can-Fite Biopharma Ltd26 Ben Gurion StreetRAMAT GAN 5257346IsraelISR
  • Phone+972 39241114
  • Fax+972 39249378
  • Websitehttps://www.canfite.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Millennium Food-Tech LP464.00k-25.91m15.11m2.00--0.1344--32.56-0.9204-0.92040.0183.440.0038--3.40232,000.00-21.38---21.52-------5,584.27-----0.170.00--224.48---84.01------
Kadimastem Ltd0.00-12.01m20.55m32.00---------1.22-1.220.00-1.040.00-------115.17-155.33-1,153.60-1,831.12-----------9.443.22------47.14---50.73--
Nextage Therapeutics Ltd876.00k-4.07m24.11m--------27.53-0.1396-0.13960.03-0.09580.672--6.82---322.44-188.94---423.7625.6833.33-479.79-2,486.19---18.46------17.9927.21------
Tikun Olam Cannbit Pharmaceuticals Ltd44.23m-88.89m30.59m51.00--0.7127--0.6916-1.43-1.430.70180.50510.3792.8719.85867,215.70-80.56-30.17-99.81-35.04-0.4273---212.57-146.420.5033-30.020.3778---10.28---84.28---8.71--
Wilk Technologies Ltd0.00-10.93m37.66m4.00--5.45-----0.1807-0.18070.000.10060.00-------80.10-266.55-96.15-298.65-------97,340.88---39.620.4049------36.02------
Grace Breeding Ltd463.00k-8.50m44.94m----28.34--97.05-2.36-2.250.12960.39980.08482.730.9636---164.09---206.24--80.56---1,935.21--1.45-94.740.5103--121.53--23.10------
X T L Biopharmaceuticals Ltd1.69m-83.65m45.58m33.00--0.5451--26.99-0.3798-0.37980.00770.15350.0192--0.701251,169.93-94.96-53.17-111.98-59.10---2.33-4,953.75-1,084.42----0.00---85.80---7.97---53.12--
Cannassure Therapeutics Ltd11.00m-1.18m50.23m------180.694.57-1.43-2.1613.28-3.660.53291.374.47---5.74-45.39-18.34-92.4129.17---10.77-83.490.04740.9011-----67.44--78.37---72.23--
Can Fite Biopharma Ltd2.76m-28.39m55.83m5.00--2.18--20.20-0.0226-0.02260.00220.01710.0771----552,702.80-79.22-102.29-103.51-131.07-----1,027.46-1,105.36----0.00---8.27-27.9224.96---42.92--
Purple Biotech Ltd0.00-69.79m59.53m20.00--0.5149-----0.2753-0.27530.000.420.00----0.00-40.57-37.24-47.99-41.28-------9,415.70----0.0098------8.25---28.45--
Matricelf Ltd0.00-13.83m70.04m----2.60-----0.8777-0.87770.001.670.00-------39.69---42.80--------------0.0527-------10.77------
DNA Group TR Ltd306.00k-1.18m96.19m14.00--1.21--314.35-0.0088-0.00880.00250.64290.0038--1.3721,857.14-1.45-23.54-1.46-26.27-----384.64-7,406.24----0.00---45.36--95.00------
GFC Green Fields Capital Ltd0.0015.70m123.57m2.007.900.78077.87--1.561.560.0015.770.00------3.261.9910.383.58------------0.00------844.9045.32----
Data as of Jun 13 2024. Currency figures normalised to Can-Fite Biopharma Ltd's reporting currency: Israeli Shekel ILS
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.